LIMN
LIMITATION FROM THE IB EXAMINED, NO ACTION IS NEEDED
11/08/2026
Voltar para busca
Dado oficial do USPTO
T ACELLT APEIRON CELL THERAPIES
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
44
Atualização mais recente
11/08/2026
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
1, 5, 42
Data de depósito
03/08/2020
Data de registro
26/07/2022
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
26/07/2022
Última transação
11/08/2026
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
98
Localização do titular
AT
Examinador
EISNACH, MICHAEL PATRICK
Unidade examinadora
L40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of the wording "ACELLT" with the "A" in blue font, the "T" in orange font, and the remaining letters in gray font. Below this is the wording "APEIRON CELL THERAPIES" in gray font. To the left of all the wording is stylized infinity symbol with the left portion of the symbol in blue, the middle of the symbol is an orange stylized "T" and the right portion of the symbol is gray. The white in the mark is background only and is not claimed as a feature of the mark.
Titulares e representantes
Titulares
APEIRON Biologics GmbH
APEIRON BIOLOGICS AG
Representantes
Julianne Abelman Womble Bond Dickinson (US) LLP
Classificação técnica
Classes Nice
Classe 1Classe 5Classe 42
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 1
Chemicalbiochemical and biotechnological preparations for industrial and scientific purposes
Classe 5
Pharmaceutical and veterinary preparationspharmaceutical preparations for treating and preventing cancerpharmaceutical preparations for cellular therapy; diagnostic preparations for medical purposes; sanitary preparations for medical purposes
Classe 42
Scientific and technological services and research and design relating theretoin particular analysis services in the field of researchdevelopment and diagnosticsscientific researchmedical research for medical applicationsdevelopment of new products for others; industrial analysis and research services in the field of cancer treatmentcell processingcellular therapy
Publicações
Histórico de despachos e eventos da marca no USPTO.
44 publicações encontradas
RHRD
RESTRICTION OF HOLDER'S RIGHT OF DISPOSAL RECEIVED
09/05/2025
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
16/01/2025
NREP
NEW REPRESENTATIVE AT IB RECEIVED
04/11/2023
FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
20/11/2022
FICS
FINAL DISPOSITION NOTICE SENT TO IB
28/10/2022
FIMP
FINAL DISPOSITION PROCESSED
27/10/2022
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
26/10/2022
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
26/07/2022
R.PR
REGISTERED-PRINCIPAL REGISTER
26/07/2022
TCCA
TEAS CHANGE OF CORRESPONDENCE RECEIVED
20/07/2022
ECDR
TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
20/07/2022
ARAA
ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
20/07/2022
REAP
TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
20/07/2022
GPNX
NOTIFICATION PROCESSED BY IB
15/05/2022
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
10/05/2022
PUBO
PUBLISHED FOR OPPOSITION
10/05/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
20/04/2022
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
20/04/2022
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
20/04/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
04/04/2022
XAEC
EXAMINER'S AMENDMENT ENTERED
04/04/2022
GNEN
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
04/04/2022
GNEA
EXAMINERS AMENDMENT E-MAILED
04/04/2022
CNEA
EXAMINERS AMENDMENT -WRITTEN
04/04/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
21/03/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
02/03/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
02/03/2022
NREP
NEW REPRESENTATIVE AT IB RECEIVED
26/11/2021
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
23/06/2021
GNFR
FINAL REFUSAL E-MAILED
23/06/2021
CNFR
FINAL REFUSAL WRITTEN
23/06/2021
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
20/05/2021
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
19/05/2021
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
19/05/2021
RFNT
REFUSAL PROCESSED BY IB
27/12/2020
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
09/12/2020
RFRR
REFUSAL PROCESSED BY MPU
09/12/2020
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
01/12/2020
CNRT
NON-FINAL ACTION WRITTEN
30/11/2020
DOCK
ASSIGNED TO EXAMINER
24/11/2020
MAFR
APPLICATION FILING RECEIPT MAILED
09/10/2020
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
05/10/2020
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
01/10/2020
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace T ACELLT APEIRON CELL THERAPIES ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.